Consolidation in the pharmaceutical industry – an outlook for 2019

Mar 18th 2019 Author:

Michael Jewell

View Profile

Last year was an extraordinary period for consolidation in the pharmaceutical industry, with mergers and acquisitions (M&A) deals globally reaching $265 billion, a more than 25% surge on 2017.

As big pharma looks to increase pipelines of innovative and orphan drugs, particularly in the biopharma sub-sector, mega deals dominated the scene.

Read full article in Pharma Letter